India tightens scrutiny of GLP-1 weight-loss drug marketing and distribution
State drug regulators have been asked to step up oversight of GLP-1 manufacturing, sales, supply-chain diversion and advertising, with a focus on surrogate promotions and misleading weight-loss campaigns.
India has directed state drug regulators to intensify oversight of GLP-1 drug manufacture, distribution, sale and advertising, targeting unauthorised supply-chain diversion, surrogate marketing and misleading weight-loss awareness campaigns.
Why this matters
The GLP-1 action extends CDSCO's wider enforcement push, following action against 90% of high-risk drug facilities inspected since late 2022 and plans for an end-to-end digital drug regulation platform.
The retail-company theme is accelerating, up +202743% QoQ.